Biofrontera Inc. (NASDAQ: BFRIW) Stock Competitors & Peer Comparison
See BFRIW's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for BFRIW and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BFRIW | $0.03 | -1.00% | 16.8M | -0.03 | -$1.12 | N/A |
| TAK | $17.48 | -0.40% | 55.6B | 12.57 | $1.39 | +3.60% |
| HLN | $9.93 | +0.00% | 43.8B | 18.53 | $0.54 | +1.77% |
| TEVA | $36.48 | +0.94% | 42.5B | 12.45 | $2.93 | N/A |
| VTRS | $16.28 | +0.00% | 19B | 6.46 | $2.52 | +2.95% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| ELAN | $22.73 | +2.02% | 11.4B | 21.46 | $1.06 | N/A |
| RDY | $12.45 | +2.47% | 10.4B | 20.39 | $0.61 | +0.67% |
| LNTH | $100.68 | -0.30% | 6.6B | 16.92 | $5.95 | N/A |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
BFRIW vs TAK Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, TAK has a market cap of 55.6B. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while TAK trades at $17.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas TAK's P/E ratio is 12.57. In terms of profitability, BFRIW's ROE is -4.77%, compared to TAK's ROE of +0.02%. Regarding short-term risk, BFRIW is less volatile compared to TAK. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check TAK's competition here
Haleon plc (NYSE: HLN)
BFRIW vs HLN Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, HLN has a market cap of 43.8B. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while HLN trades at $9.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas HLN's P/E ratio is 18.53. In terms of profitability, BFRIW's ROE is -4.77%, compared to HLN's ROE of +0.17%. Regarding short-term risk, BFRIW is less volatile compared to HLN. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check HLN's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
BFRIW vs TEVA Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, TEVA has a market cap of 42.5B. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while TEVA trades at $36.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas TEVA's P/E ratio is 12.45. In terms of profitability, BFRIW's ROE is -4.77%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, BFRIW is less volatile compared to TEVA. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check TEVA's competition here
Viatris Inc. (NASDAQ: VTRS)
BFRIW vs VTRS Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, VTRS has a market cap of 19B. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while VTRS trades at $16.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas VTRS's P/E ratio is 6.46. In terms of profitability, BFRIW's ROE is -4.77%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, BFRIW is less volatile compared to VTRS. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
BFRIW vs ITCI Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas ITCI's P/E ratio is -180.64. In terms of profitability, BFRIW's ROE is -4.77%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, BFRIW is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for BFRIW.Check ITCI's competition here
Catalent, Inc. (NYSE: CTLT)
BFRIW vs CTLT Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas CTLT's P/E ratio is -27.84. In terms of profitability, BFRIW's ROE is -4.77%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, BFRIW is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for BFRIW.Check CTLT's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
BFRIW vs ELAN Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, ELAN has a market cap of 11.4B. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while ELAN trades at $22.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas ELAN's P/E ratio is 21.46. In terms of profitability, BFRIW's ROE is -4.77%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, BFRIW is less volatile compared to ELAN. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check ELAN's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
BFRIW vs RDY Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, RDY has a market cap of 10.4B. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while RDY trades at $12.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas RDY's P/E ratio is 20.39. In terms of profitability, BFRIW's ROE is -4.77%, compared to RDY's ROE of +0.09%. Regarding short-term risk, BFRIW is less volatile compared to RDY. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check RDY's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
BFRIW vs LNTH Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while LNTH trades at $100.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas LNTH's P/E ratio is 16.92. In terms of profitability, BFRIW's ROE is -4.77%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, BFRIW is less volatile compared to LNTH. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
BFRIW vs AMRX Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, AMRX has a market cap of 5.5B. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while AMRX trades at $17.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas AMRX's P/E ratio is 19.00. In terms of profitability, BFRIW's ROE is -4.77%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, BFRIW is less volatile compared to AMRX. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check AMRX's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
BFRIW vs INDV Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, INDV has a market cap of 4.8B. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while INDV trades at $38.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas INDV's P/E ratio is 10.53. In terms of profitability, BFRIW's ROE is -4.77%, compared to INDV's ROE of -2.16%. Regarding short-term risk, BFRIW is less volatile compared to INDV. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check INDV's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
BFRIW vs SUPN Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, SUPN has a market cap of 2.7B. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while SUPN trades at $46.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas SUPN's P/E ratio is 15.32. In terms of profitability, BFRIW's ROE is -4.77%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, BFRIW is less volatile compared to SUPN. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check SUPN's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
BFRIW vs RGC Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, RGC has a market cap of 2.5B. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while RGC trades at $5.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas RGC's P/E ratio is -353.52. In terms of profitability, BFRIW's ROE is -4.77%, compared to RGC's ROE of -2.32%. Regarding short-term risk, BFRIW is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check RGC's competition here
Bausch Health Companies Inc. (NYSE: BHC)
BFRIW vs BHC Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, BHC has a market cap of 2.3B. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while BHC trades at $6.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas BHC's P/E ratio is 1.59. In terms of profitability, BFRIW's ROE is -4.77%, compared to BHC's ROE of +0.89%. Regarding short-term risk, BFRIW is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check BHC's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
BFRIW vs DCPH Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas DCPH's P/E ratio is -11.58. In terms of profitability, BFRIW's ROE is -4.77%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, BFRIW is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for BFRIW.Check DCPH's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
BFRIW vs HCM Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, HCM has a market cap of 2.2B. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while HCM trades at $12.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas HCM's P/E ratio is 4.67. In terms of profitability, BFRIW's ROE is -4.77%, compared to HCM's ROE of +0.01%. Regarding short-term risk, BFRIW is less volatile compared to HCM. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check HCM's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
BFRIW vs AVDL Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, BFRIW's ROE is -4.77%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, BFRIW is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for BFRIW.Check AVDL's competition here
Embecta Corp. (NASDAQ: EMBCV)
BFRIW vs EMBCV Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas EMBCV's P/E ratio is N/A. In terms of profitability, BFRIW's ROE is -4.77%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, BFRIW is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
BFRIW vs DVAX Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas DVAX's P/E ratio is -41.89. In terms of profitability, BFRIW's ROE is -4.77%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, BFRIW is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for BFRIW.Check DVAX's competition here
Perrigo Company plc (NYSE: PRGO)
BFRIW vs PRGO Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, PRGO has a market cap of 1.8B. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while PRGO trades at $12.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas PRGO's P/E ratio is 5.14. In terms of profitability, BFRIW's ROE is -4.77%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, BFRIW is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check PRGO's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
BFRIW vs ANIP Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while ANIP trades at $74.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas ANIP's P/E ratio is 9.07. In terms of profitability, BFRIW's ROE is -4.77%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, BFRIW is less volatile compared to ANIP. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check ANIP's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
BFRIW vs TARO Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas TARO's P/E ratio is 30.05. In terms of profitability, BFRIW's ROE is -4.77%, compared to TARO's ROE of +0.03%. Regarding short-term risk, BFRIW is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for BFRIW.Check TARO's competition here
Harrow Health, Inc. (NASDAQ: HROW)
BFRIW vs HROW Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, HROW has a market cap of 1.5B. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while HROW trades at $39.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas HROW's P/E ratio is 438.00. In terms of profitability, BFRIW's ROE is -4.77%, compared to HROW's ROE of -1.04%. Regarding short-term risk, BFRIW is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check HROW's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
BFRIW vs PAHC Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while PAHC trades at $34.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas PAHC's P/E ratio is 11.63. In terms of profitability, BFRIW's ROE is -4.77%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, BFRIW is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check PAHC's competition here
Alvotech (NASDAQ: ALVO)
BFRIW vs ALVO Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, ALVO has a market cap of 1.3B. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while ALVO trades at $3.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas ALVO's P/E ratio is -11.18. In terms of profitability, BFRIW's ROE is -4.77%, compared to ALVO's ROE of +0.35%. Regarding short-term risk, BFRIW is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check ALVO's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
BFRIW vs ETON Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, ETON has a market cap of 1.2B. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while ETON trades at $42.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas ETON's P/E ratio is -600.71. In terms of profitability, BFRIW's ROE is -4.77%, compared to ETON's ROE of -0.06%. Regarding short-term risk, BFRIW is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check ETON's competition here
Cronos Group Inc. (NASDAQ: CRON)
BFRIW vs CRON Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while CRON trades at $3.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas CRON's P/E ratio is 29.25. In terms of profitability, BFRIW's ROE is -4.77%, compared to CRON's ROE of +0.06%. Regarding short-term risk, BFRIW is less volatile compared to CRON. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check CRON's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
BFRIW vs PCRX Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, PCRX has a market cap of 959M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while PCRX trades at $24.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas PCRX's P/E ratio is 9.38. In terms of profitability, BFRIW's ROE is -4.77%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, BFRIW is less volatile compared to PCRX. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check PCRX's competition here
PetIQ, Inc. (NASDAQ: PETQ)
BFRIW vs PETQ Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas PETQ's P/E ratio is 83.73. In terms of profitability, BFRIW's ROE is -4.77%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, BFRIW is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for BFRIW.Check PETQ's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
BFRIW vs AMPH Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, AMPH has a market cap of 900.4M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while AMPH trades at $20.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas AMPH's P/E ratio is 6.97. In terms of profitability, BFRIW's ROE is -4.77%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, BFRIW is less volatile compared to AMPH. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check AMPH's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
BFRIW vs COLL Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, COLL has a market cap of 842.6M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while COLL trades at $25.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas COLL's P/E ratio is 3.26. In terms of profitability, BFRIW's ROE is -4.77%, compared to COLL's ROE of +0.16%. Regarding short-term risk, BFRIW is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check COLL's competition here
Evotec SE (NASDAQ: EVO)
BFRIW vs EVO Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, EVO has a market cap of 746M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while EVO trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas EVO's P/E ratio is -2.97. In terms of profitability, BFRIW's ROE is -4.77%, compared to EVO's ROE of -0.24%. Regarding short-term risk, BFRIW is less volatile compared to EVO. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check EVO's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
BFRIW vs IRWD Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, IRWD has a market cap of 707.8M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while IRWD trades at $4.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas IRWD's P/E ratio is 5.51. In terms of profitability, BFRIW's ROE is -4.77%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, BFRIW is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check IRWD's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
BFRIW vs BDSI Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas BDSI's P/E ratio is 6.82. In terms of profitability, BFRIW's ROE is -4.77%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, BFRIW is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for BFRIW.Check BDSI's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
BFRIW vs AQST Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, AQST has a market cap of 553.3M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while AQST trades at $4.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas AQST's P/E ratio is -7.23. In terms of profitability, BFRIW's ROE is -4.77%, compared to AQST's ROE of +1.91%. Regarding short-term risk, BFRIW is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check AQST's competition here
Evolus, Inc. (NASDAQ: EOLS)
BFRIW vs EOLS Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, EOLS has a market cap of 549.2M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while EOLS trades at $8.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas EOLS's P/E ratio is -26.41. In terms of profitability, BFRIW's ROE is -4.77%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, BFRIW is less volatile compared to EOLS. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check EOLS's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
BFRIW vs TLRY Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, TLRY has a market cap of 534.6M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while TLRY trades at $4.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas TLRY's P/E ratio is -4.41. In terms of profitability, BFRIW's ROE is -4.77%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, BFRIW is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check TLRY's competition here
Canopy Growth Corporation (NASDAQ: CGC)
BFRIW vs CGC Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, CGC has a market cap of 422.2M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while CGC trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas CGC's P/E ratio is -0.60. In terms of profitability, BFRIW's ROE is -4.77%, compared to CGC's ROE of -0.33%. Regarding short-term risk, BFRIW is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check CGC's competition here
Kamada Ltd. (NASDAQ: KMDA)
BFRIW vs KMDA Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, KMDA has a market cap of 409.1M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while KMDA trades at $7.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas KMDA's P/E ratio is 20.26. In terms of profitability, BFRIW's ROE is -4.77%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, BFRIW is less volatile compared to KMDA. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check KMDA's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
BFRIW vs TKNO Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, TKNO has a market cap of 377.4M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while TKNO trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas TKNO's P/E ratio is -22.71. In terms of profitability, BFRIW's ROE is -4.77%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, BFRIW is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check TKNO's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
BFRIW vs ALIM Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas ALIM's P/E ratio is 5.28. In terms of profitability, BFRIW's ROE is -4.77%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, BFRIW is less volatile compared to ALIM. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check ALIM's competition here
Embecta Corp. (NASDAQ: EMBC)
BFRIW vs EMBC Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, EMBC has a market cap of 289.5M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while EMBC trades at $4.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas EMBC's P/E ratio is 1.88. In terms of profitability, BFRIW's ROE is -4.77%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, BFRIW is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check EMBC's competition here
Landec Corporation (NASDAQ: LNDC)
BFRIW vs LNDC Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas LNDC's P/E ratio is -4.04. In terms of profitability, BFRIW's ROE is -4.77%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, BFRIW is less volatile compared to LNDC. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check LNDC's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
BFRIW vs ORGO Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, ORGO has a market cap of 243.2M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while ORGO trades at $1.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas ORGO's P/E ratio is 63.00. In terms of profitability, BFRIW's ROE is -4.77%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, BFRIW is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check ORGO's competition here
Shineco, Inc. (NASDAQ: TYHT)
BFRIW vs TYHT Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas TYHT's P/E ratio is -1.61. In terms of profitability, BFRIW's ROE is -4.77%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, BFRIW is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check TYHT's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
BFRIW vs ACB Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, ACB has a market cap of 215.6M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while ACB trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas ACB's P/E ratio is -7.10. In terms of profitability, BFRIW's ROE is -4.77%, compared to ACB's ROE of -0.21%. Regarding short-term risk, BFRIW is less volatile compared to ACB. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check ACB's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
BFRIW vs SIGA Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, SIGA has a market cap of 206.6M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while SIGA trades at $2.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas SIGA's P/E ratio is 10.67. In terms of profitability, BFRIW's ROE is -4.77%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, BFRIW is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check SIGA's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
BFRIW vs LFCR Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, LFCR has a market cap of 181.2M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while LFCR trades at $4.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas LFCR's P/E ratio is -4.51. In terms of profitability, BFRIW's ROE is -4.77%, compared to LFCR's ROE of -2.51%. Regarding short-term risk, BFRIW is less volatile compared to LFCR. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check LFCR's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
BFRIW vs REPH Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas REPH's P/E ratio is -8.04. In terms of profitability, BFRIW's ROE is -4.77%, compared to REPH's ROE of -0.22%. Regarding short-term risk, BFRIW is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check REPH's competition here
Journey Medical Corporation (NASDAQ: DERM)
BFRIW vs DERM Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, DERM has a market cap of 173.9M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while DERM trades at $6.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas DERM's P/E ratio is -17.08. In terms of profitability, BFRIW's ROE is -4.77%, compared to DERM's ROE of -0.36%. Regarding short-term risk, BFRIW is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check DERM's competition here
Organigram Global Inc. (NASDAQ: OGI)
BFRIW vs OGI Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, OGI has a market cap of 173.2M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while OGI trades at $1.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas OGI's P/E ratio is -4.73. In terms of profitability, BFRIW's ROE is -4.77%, compared to OGI's ROE of -0.07%. Regarding short-term risk, BFRIW is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check OGI's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
BFRIW vs CRDL Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, CRDL has a market cap of 172.9M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while CRDL trades at $1.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas CRDL's P/E ratio is -5.34. In terms of profitability, BFRIW's ROE is -4.77%, compared to CRDL's ROE of -2.29%. Regarding short-term risk, BFRIW is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check CRDL's competition here
Theratechnologies Inc. (NASDAQ: THTX)
BFRIW vs THTX Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas THTX's P/E ratio is -28.83. In terms of profitability, BFRIW's ROE is -4.77%, compared to THTX's ROE of +0.17%. Regarding short-term risk, BFRIW is less volatile compared to THTX. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
BFRIW vs ASRT Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas ASRT's P/E ratio is -7.10. In terms of profitability, BFRIW's ROE is -4.77%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, BFRIW is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for BFRIW.Check ASRT's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
BFRIW vs CPIX Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, CPIX has a market cap of 119.3M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while CPIX trades at $7.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas CPIX's P/E ratio is -19.90. In terms of profitability, BFRIW's ROE is -4.77%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, BFRIW is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check CPIX's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
BFRIW vs SCTL Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas SCTL's P/E ratio is -7.86. In terms of profitability, BFRIW's ROE is -4.77%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, BFRIW is less volatile compared to SCTL. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check SCTL's competition here
BGM Group Ltd. (NASDAQ: BGM)
BFRIW vs BGM Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, BGM has a market cap of 110.8M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while BGM trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas BGM's P/E ratio is -1.00. In terms of profitability, BFRIW's ROE is -4.77%, compared to BGM's ROE of -0.07%. Regarding short-term risk, BFRIW is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check BGM's competition here
Procaps Group S.A. (NASDAQ: PROC)
BFRIW vs PROC Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas PROC's P/E ratio is 1.53. In terms of profitability, BFRIW's ROE is -4.77%, compared to PROC's ROE of -2.22%. Regarding short-term risk, BFRIW is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for BFRIW.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
BFRIW vs OPTN Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas OPTN's P/E ratio is -4.42. In terms of profitability, BFRIW's ROE is -4.77%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, BFRIW is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for BFRIW.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
BFRIW vs ZOM Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas ZOM's P/E ratio is -1.62. In terms of profitability, BFRIW's ROE is -4.77%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, BFRIW is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
BFRIW vs GRVI Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas GRVI's P/E ratio is 26.05. In terms of profitability, BFRIW's ROE is -4.77%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, BFRIW is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check GRVI's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
BFRIW vs ZYBT Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, ZYBT has a market cap of 77.7M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while ZYBT trades at $1.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas ZYBT's P/E ratio is -7.45. In terms of profitability, BFRIW's ROE is -4.77%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, BFRIW is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check ZYBT's competition here
Talphera, Inc. (NASDAQ: TLPH)
BFRIW vs TLPH Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, TLPH has a market cap of 76.3M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while TLPH trades at $1.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas TLPH's P/E ratio is -4.74. In terms of profitability, BFRIW's ROE is -4.77%, compared to TLPH's ROE of -0.93%. Regarding short-term risk, BFRIW is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check TLPH's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
BFRIW vs ZYNE Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, BFRIW's ROE is -4.77%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, BFRIW is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
BFRIW vs SSIC Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas SSIC's P/E ratio is 11.93. In terms of profitability, BFRIW's ROE is -4.77%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, BFRIW is less volatile compared to SSIC. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check SSIC's competition here
The Valens Company Inc. (NASDAQ: VLNS)
BFRIW vs VLNS Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas VLNS's P/E ratio is -1.03. In terms of profitability, BFRIW's ROE is -4.77%, compared to VLNS's ROE of N/A. Regarding short-term risk, BFRIW is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
BFRIW vs DRRX Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas DRRX's P/E ratio is -4.44. In terms of profitability, BFRIW's ROE is -4.77%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, BFRIW is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for BFRIW.Check DRRX's competition here
InterCure Ltd. (NASDAQ: INCR)
BFRIW vs INCR Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, INCR has a market cap of 59.2M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while INCR trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas INCR's P/E ratio is -2.31. In terms of profitability, BFRIW's ROE is -4.77%, compared to INCR's ROE of -0.09%. Regarding short-term risk, BFRIW is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check INCR's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
BFRIW vs JUPW Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas JUPW's P/E ratio is -2.41. In terms of profitability, BFRIW's ROE is -4.77%, compared to JUPW's ROE of -1.94%. Regarding short-term risk, BFRIW is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check JUPW's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
BFRIW vs CPHI Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, CPHI has a market cap of 44.6M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while CPHI trades at $1.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas CPHI's P/E ratio is -1.72. In terms of profitability, BFRIW's ROE is -4.77%, compared to CPHI's ROE of -0.19%. Regarding short-term risk, BFRIW is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check CPHI's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
BFRIW vs QLI Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas QLI's P/E ratio is -4.92. In terms of profitability, BFRIW's ROE is -4.77%, compared to QLI's ROE of -0.16%. Regarding short-term risk, BFRIW is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for BFRIW.Check QLI's competition here
HEXO Corp. (NASDAQ: HEXO)
BFRIW vs HEXO Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas HEXO's P/E ratio is -0.26. In terms of profitability, BFRIW's ROE is -4.77%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, BFRIW is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check HEXO's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
BFRIW vs RMTI Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, RMTI has a market cap of 27.9M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while RMTI trades at $7.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas RMTI's P/E ratio is -6.74. In terms of profitability, BFRIW's ROE is -4.77%, compared to RMTI's ROE of -0.15%. Regarding short-term risk, BFRIW is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check RMTI's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
BFRIW vs AYTU Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, AYTU has a market cap of 25.8M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while AYTU trades at $2.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas AYTU's P/E ratio is -1.25. In terms of profitability, BFRIW's ROE is -4.77%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, BFRIW is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check AYTU's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
BFRIW vs TXMD Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, TXMD has a market cap of 24M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while TXMD trades at $2.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas TXMD's P/E ratio is 105.45. In terms of profitability, BFRIW's ROE is -4.77%, compared to TXMD's ROE of +0.01%. Regarding short-term risk, BFRIW is less volatile compared to TXMD. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check TXMD's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
BFRIW vs CYTH Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas CYTH's P/E ratio is -0.80. In terms of profitability, BFRIW's ROE is -4.77%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, BFRIW is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for BFRIW.Check CYTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
BFRIW vs EVOK Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas EVOK's P/E ratio is -7.97. In terms of profitability, BFRIW's ROE is -4.77%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, BFRIW is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for BFRIW.Check EVOK's competition here
Optimi Health Corp. (NASDAQ: OPTH)
BFRIW vs OPTH Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, OPTH has a market cap of 15.1M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while OPTH trades at $4.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas OPTH's P/E ratio is -17.13. In terms of profitability, BFRIW's ROE is -4.77%, compared to OPTH's ROE of -0.94%. Regarding short-term risk, BFRIW is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
BFRIW vs ACRX Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas ACRX's P/E ratio is -0.31. In terms of profitability, BFRIW's ROE is -4.77%, compared to ACRX's ROE of -0.93%. Regarding short-term risk, BFRIW is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check ACRX's competition here
Cosmos Health Inc. (NASDAQ: COSM)
BFRIW vs COSM Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, COSM has a market cap of 11.7M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while COSM trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas COSM's P/E ratio is -0.29. In terms of profitability, BFRIW's ROE is -4.77%, compared to COSM's ROE of -0.96%. Regarding short-term risk, BFRIW is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check COSM's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
BFRIW vs AGRX Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas AGRX's P/E ratio is -0.89. In terms of profitability, BFRIW's ROE is -4.77%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, BFRIW is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
BFRIW vs NLTX Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas NLTX's P/E ratio is -0.28. In terms of profitability, BFRIW's ROE is -4.77%, compared to NLTX's ROE of -0.38%. Regarding short-term risk, BFRIW is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
BFRIW vs LCI Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas LCI's P/E ratio is -0.04. In terms of profitability, BFRIW's ROE is -4.77%, compared to LCI's ROE of +1.66%. Regarding short-term risk, BFRIW is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
BFRIW vs ADMP Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas ADMP's P/E ratio is -0.08. In terms of profitability, BFRIW's ROE is -4.77%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, BFRIW is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check ADMP's competition here
cbdMD, Inc. (AMEX: YCBD)
BFRIW vs YCBD Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, YCBD has a market cap of 6M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while YCBD trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas YCBD's P/E ratio is -1.41. In terms of profitability, BFRIW's ROE is -4.77%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, BFRIW is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check YCBD's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
BFRIW vs GELS Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, GELS has a market cap of 5.2M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while GELS trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas GELS's P/E ratio is -1.14. In terms of profitability, BFRIW's ROE is -4.77%, compared to GELS's ROE of -0.25%. Regarding short-term risk, BFRIW is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check GELS's competition here
Mallinckrodt plc (AMEX: MNK)
BFRIW vs MNK Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas MNK's P/E ratio is -0.44. In terms of profitability, BFRIW's ROE is -4.77%, compared to MNK's ROE of -0.36%. Regarding short-term risk, BFRIW is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
BFRIW vs FLGC Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas FLGC's P/E ratio is -0.19. In terms of profitability, BFRIW's ROE is -4.77%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, BFRIW is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check FLGC's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
BFRIW vs UPC Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, UPC has a market cap of 3.8M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while UPC trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas UPC's P/E ratio is -0.74. In terms of profitability, BFRIW's ROE is -4.77%, compared to UPC's ROE of -0.03%. Regarding short-term risk, BFRIW is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check UPC's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
BFRIW vs SBFM Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, SBFM has a market cap of 2.9M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while SBFM trades at $1.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas SBFM's P/E ratio is -0.20. In terms of profitability, BFRIW's ROE is -4.77%, compared to SBFM's ROE of -0.26%. Regarding short-term risk, BFRIW is less volatile compared to SBFM. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check SBFM's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
BFRIW vs PLXP Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas PLXP's P/E ratio is -0.22. In terms of profitability, BFRIW's ROE is -4.77%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, BFRIW is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check PLXP's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
BFRIW vs SHPH Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, SHPH has a market cap of 2.5M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while SHPH trades at $4.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas SHPH's P/E ratio is -0.20. In terms of profitability, BFRIW's ROE is -4.77%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, BFRIW is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check SHPH's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
BFRIW vs SNOA Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, SNOA has a market cap of 2.4M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while SNOA trades at $1.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas SNOA's P/E ratio is -1.19. In terms of profitability, BFRIW's ROE is -4.77%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, BFRIW is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check SNOA's competition here
Athenex, Inc. (NASDAQ: ATNX)
BFRIW vs ATNX Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas ATNX's P/E ratio is -0.02. In terms of profitability, BFRIW's ROE is -4.77%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, BFRIW is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for BFRIW.Check ATNX's competition here
Procaps Group, S.A. (NASDAQ: PROCW)
BFRIW vs PROCW Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while PROCW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas PROCW's P/E ratio is N/A. In terms of profitability, BFRIW's ROE is -4.77%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, BFRIW is more volatile compared to PROCW. This indicates higher risk in terms of short-term price fluctuations for BFRIW.Check PROCW's competition here
RedHill Biopharma Ltd. (NASDAQ: RDHL)
BFRIW vs RDHL Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, RDHL has a market cap of 1.9M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while RDHL trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas RDHL's P/E ratio is 0.12. In terms of profitability, BFRIW's ROE is -4.77%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, BFRIW is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check RDHL's competition here
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC)
BFRIW vs SXTC Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, SXTC has a market cap of 1.9M. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while SXTC trades at $3.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas SXTC's P/E ratio is 1.25. In terms of profitability, BFRIW's ROE is -4.77%, compared to SXTC's ROE of -0.31%. Regarding short-term risk, BFRIW is less volatile compared to SXTC. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check SXTC's competition here
cbdMD, Inc. (AMEX: YCBD-PA)
BFRIW vs YCBD-PA Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, YCBD-PA has a market cap of 928.2K. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while YCBD-PA trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas YCBD-PA's P/E ratio is -2.69. In terms of profitability, BFRIW's ROE is -4.77%, compared to YCBD-PA's ROE of -0.34%. Regarding short-term risk, BFRIW is less volatile compared to YCBD-PA. This indicates lower risk in terms of short-term price fluctuations for BFRIW.Check YCBD-PA's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTHW)
BFRIW vs CYTHW Comparison August 2026
Biofrontera Inc. (NASDAQ: BFRIW) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BFRIW stands at 16.8M. In comparison, CYTHW has a market cap of 928K. Regarding current trading prices, BFRIW is priced at $0.03 on the NASDAQ, while CYTHW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BFRIW currently has a P/E ratio of -0.03, whereas CYTHW's P/E ratio is N/A. In terms of profitability, BFRIW's ROE is -4.77%, compared to CYTHW's ROE of -7.30%. Regarding short-term risk, BFRIW is more volatile compared to CYTHW. This indicates higher risk in terms of short-term price fluctuations for BFRIW.Check CYTHW's competition here